We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Allergy Therapeutics
G309 exploratory grass trial on course for H221 read-outFutura Medical
MED3000 receives CE Mark as a Class II(b) deviceMaxCyte
Catching an unbroken waveFutura Medical
FY21 is set to be a year of executionHUTCHMED
Baring Private Equity Asia invests $100mNexstim
Rights issue 178% oversubscribedHUTCHMED
Breaking new ground in China and globallyFutura Medical
EU Notified Body recommends MED3000 approvalNexstim
Subscription rights issue of €6.6m at €0.03 per shareHutchison China MediTech
Transitioning to a global oncology player